CDK17

Across TCGA pan-cancer cohorts, CDK17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDK17 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDK17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDK17 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where CDK17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.308	0.524	.006	37	view →
CCRCC	DFS	Median	III,IV	0.718	0.445	.013	6	view →
GBM	OS	Quartile	All	0.648	0.257	.018	4	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDK17–PDAC (DFS)

Open the PDAC breakdown →